ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.

Andreone, Pietro, Colombo, Massimo G, Enejosa, Jeffrey V, Koksal, Iftihar, Ferenci, Peter, Maieron, Andreas, Müllhaupt, Beat, Horsmans, Yves, Weiland, Ola, Reesink, Henk W, Rodrigues, Lino, Hu, Yiran B, Podsadecki, Thomas and Bernstein, Barry (2014) ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology, 147 (2). 359-365.e1. ISSN 1528-0012

Full text not available from this repository.

Item Type:	Article
Divisions:	Ordensklinikum Linz Elisabethinen > Interne 4 - Gastroenterologie & Hepatologie, Stoffwechsel & Ernährungsmedizin, Endokrinologie
Depositing User:	Prof. Dr. Rainer Schöfl
Date Deposited:	29 Oct 2019 12:32
Last Modified:	17 Feb 2025 09:33
URI:	https://eprints.vinzenzgruppe.at/id/eprint/8777

Edit Item